SCHEMBL3525448

SCHEMBL3525448

CC(OS(=O)(=O)C(F)(F)F)C(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
CTSL P07711 1/20 0.43
CTSS P25774 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
MAPK1 P28482 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
CTSK P43235 2/20 0.41
ELANE P08246 1/20 0.41
ACHE P22303 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20276639 1.00 ALDH1A1 (0.47) ALDH1A1L3MBTL1LMNAKMT2AMEN1
SCHEMBL18256487 1.00 ALDH1A1 (0.47) ALDH1A1L3MBTL1LMNAKMT2AMEN1
SCHEMBL8248815 0.90 ALDH1A1 (0.44) ALDH1A1L3MBTL1LMNAKMT2AMEN1
SCHEMBL5222478 0.86 ALDH1A1 (0.45) ALDH1A1L3MBTL1LMNAKMT2AMEN1
SCHEMBL203089 0.86 ALDH1A1 (0.45) ALDH1A1L3MBTL1LMNAKMT2AMEN1
SCHEMBL3913155 0.86 ALDH1A1 (0.45) ALDH1A1L3MBTL1LMNAKMT2AMEN1
SCHEMBL8874165 0.86 ALDH1A1 (0.45) ALDH1A1L3MBTL1LMNAKMT2AMEN1
SCHEMBL7313485 0.83 CTSK (0.43) ALDH1A1CTSLCTSSCTSK
SCHEMBL5870158 0.83 CTSK (0.43) ALDH1A1CTSLCTSSCTSK
SCHEMBL22402324 0.83 ALDH1A1 (0.51) ALDH1A1L3MBTL1LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081473-A1 A PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}-1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B] [1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE BRISTOL-MYERS SQUIBB COMPANY (US) 2022-04-21 WO disclosed
EP-1575901-B1 SUBSTITUTED AMIDES MERCK SHARP & DOHME (US) 2012-10-10 EP disclosed
US-7816534-B2 Substituted amides MERCK SHARP & DOHME CORP. (US) 2010-10-19 US disclosed
US-20090258884-A1 Substituted amides MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-7576239-B2 Substituted amides MERCK & CO., INC. (US) 2009-08-18 US disclosed
US-7550489-B2 Substituted pyridyoxy amides MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-20090137529-A1 SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2009-05-28 US disclosed
EP-1575901-A4 SUBSTITUTED AMIDES MERCK & CO INC (US) 2009-03-18 EP disclosed
EP-2019593-A1 PRO-DRUGS OF TERTIARY ALCOHOLS Merck & Co., Inc. (US) 2009-02-04 EP disclosed
US-20080194645-A1 Substituted amides MERCK SHARP & DOHME CORP. 2008-08-14 US disclosed
EP-1450864-A2 CONJUGATES OF MACROCYCLIC METAL COMPLEXES WITH BIOMOLECULES AND THE UTILIZATION THEREOF FOR PRODUCING AGENTS FOR USE IN NMR DIAGNOSIS AND RADIODIAGNOSIS AND RADIOTHERAPY Schering AG (DE) 2004-09-01 EP disclosed
WO-2004058145-A2 SUBSTITUTED AMIDES MERCK & CO., INC. (US) 2004-07-15 WO disclosed
EP-1409024-A1 MACROCYCLIC METAL COMPLEXES AND USE THEREOF FOR PRODUCTION OF CONJUGATES WITH BIOMOLECULES Schering AG (DE) 2004-04-21 EP disclosed
US-20040058820-A1 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis MERCK SHARP & DOHME LLC 2004-03-25 US disclosed
US-20030206865-A1 Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy SCHERING AG (DE) 2003-11-06 US disclosed
WO-2003077847-A2 SUBSTITUTED AMIDES MERCK & CO., INC. (US) 2003-09-25 WO disclosed
US-20030108486-A1 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules SCHERING AG (DE) 2003-06-12 US disclosed
WO-2003013617-A2 CONJUGATES OF MACROCYCLIC METAL COMPLEXES WITH BIOMOLECULES AND THE UTILIZATION THEREOF FOR PRODUCING AGENTS FOR USE IN NMR DIAGNOSIS AND RADIODIAGNOSIS AND RADIOTHERAPY SCHERING AG (DE) 2003-02-20 WO disclosed
WO-2003009874-A1 MACROCYCLIC METAL COMPLEXES AND USE THEREOF FOR PRODUCTION OF CONJUGATES WITH BIOMOLECULES SCHERING AG (DE) 2003-02-06 WO disclosed
US-4801721-A Stereospecific synthesis of carboxyalkyl peptides RYAN JAMES W (US) 1989-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108486-A1 Macrocyclic metal complexes and their use for the production of conjugates with biomolecules CA13, MPI, CA14 ALDH1A1 3392/4885L3MBTL1 3120/4885LMNA 4252/4885
US-20030206865-A1 Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy CA13, CA14, CA12 ALDH1A1 2758/4885L3MBTL1 3119/4885LMNA 3930/4885
US-20080194645-A1 Substituted amides CNR1, CNR2, FAAH ALDH1A1 2986/4885L3MBTL1 3168/4885LMNA 1615/4885
US-20040058820-A1 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis CNR1, CNR2, MAG ALDH1A1 3568/4885L3MBTL1 3941/4885LMNA 1882/4885
US-20090137529-A1 SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS CNR1, CNR2, CHRNA10 ALDH1A1 2210/4885L3MBTL1 1971/4885LMNA 2274/4885
US-20090258884-A1 Substituted amides CNR1, CNR2, FAAH ALDH1A1 2986/4885L3MBTL1 3168/4885LMNA 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.